Lavomax tab n / 125mg of 10 pcs

Description

Composition
Active substance:
Tilorona dihydrochloride – 125 mg ;.
Excipients:
Magnesium hydroxycarbonate pentahydrate – 69 mg, povidone – 4 mg of calcium stearate – 2 mg; shell – Sucrose – 158.2 mg Povidone – 5.56 mg, copovidone – 0.44 mg magnesium hydroxycarbonate pentahydrate – 25.7 mg Titanium dioxide – 1.2 mg colloidal silicon dioxide (Aerosil A-380) – 1 mg dye tropeolin-O – 0.1 mg macrogol 6000 – 6 mg, beeswax – 0.15 mg, paraffin liquid – 0.15 mg talc – 1.5 mg.
Description:
Tablets, coated tablets, from yellow to orange in color, circular shape. The core of an orange pill.
Product form:
Coated tablets, 125 mg.
10 tablets in blisters. One or two blisters together with instructions for medical use of the drug is placed in a cardboard pack.
Contraindications
Hypersensitivity to tilorona or other components of the formulation. During pregnancy and lactation. Children’s age (18 years). Deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption (preparation contains sucrose).
Dosage
125 mg
Indications
In the combined therapy in adults: treatment of influenza and other acute respiratory viral infections; treatment of herpes infections. prevention of influenza and other acute respiratory viral infections in adults.
Interaction with other drugs
Compatible with antibiotics and traditional means of treatment of viral and bacterial diseases. Clinically significant interaction Lavomaks® medication with antibiotics, traditional means of treatment of viral and bacterial diseases, alcohol is not detected.
Overdose
Overdose cases Lavomaksa® unknown.
pharmachologic effect
Pharmacological group:
Antiviral immunostimulatory agent – interferon inducer of education.
Pharmacodynamics:
The low molecular weight synthetic inducer of interferon, stimulates the formation in the body of all types of interferon (alpha, beta, gamma and lambda). Major producers of interferon in response to tilorona are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils, and granulocytes. After ingestion maximum production of interferon is defined in the sequence intestine – liver -. Bled 4-24 hours tilorona possesses immunomodulatory and antiviral effect. According to the experimental studies after single oral administration tilorona a dose equivalent to the maximum daily dose for a person, the maximum concentration of interferon in the pulmonary tissue lambda is determined after 24 hours, interferon alpha – 48 hours. Induction of Interferon lambda in the lung tissue contributes to the antiviral protection of the respiratory tract with influenza and other respiratory viral infections. In human leukocytes induces the synthesis of interferon. Stimulates bone marrow stem cells, dose-dependently enhances antibody production, reduces the degree of immunosuppression, restores ratio of T-suppressor and T-helper cells. It is effective against a variety of viral infections, including influenza virus, and other acute respiratory viral infections, hepatitis viruses and herpes viruses. antiviral mechanism of action is associated with inhibition of translation of virus-specific proteins in infected cells, resulting in suppressed reproduction of viruses.
Pharmacokinetics:
After ingestion tilorona rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% tilorona bound to plasma proteins. Tilorona displayed virtually unchanged through the gut (70%) and the kidneys (9%). The half-life is 48 hours. Tilorona no biotransformation and does not accumulate in the body.
Pregnancy and breast-feeding
Use of the drug during pregnancy is contraindicated. If necessary, use during lactation should stop breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
Allergic reactions, dyspepsia, intermittent fever. If any of these instructions side effects are compounded, or if you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
Effects on ability to drive vehicles and operate machinery
Use of the drug has no effect on ability to drive and engage in other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
In a dry, dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
The drug is taken orally, after meals.
For the treatment of influenza and SARS – 125 mg per day in the first 2 days of treatment followed by 125 mg every 48 hours. At Course – 750 mg (6 tablets).
For the prevention of influenza and other acute respiratory viral infections – 125 mg 1 time per week for 6 weeks. At Course – 750 mg (6 tablets).
For the treatment of herpes infection – the first two days of 125 mg, followed 48 hours later by 125 mg. Heading dose – 1.25-2.5 grams (10-20 tablets).
In the treatment of influenza and other acute respiratory viral infections in case of continued symptoms of the disease for more than 4 days, you should consult a doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist